Pfizer, a multinational pharmaceutical and biotechnology corporation, is now a $159 billion (by market cap) healthcare giant.

Pfizer has low forward P/E ratios for the next five years. The FY2027 forward P/E ratio is low at 8.61. On the other hand, we see that the ratio will not shrink significantly between FY2024 and FY2027 ...

Pfizer Inc. Chief Executive Officer Albert Bourla said he’ll do “whatever it takes” to keep profits growing, including ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

Pfizer ( PFE) raised its full-year guidance by $1.5 billion and posted strong third quarter earnings Tuesday. The company now ...

Pfizer's quarterly earnings handily beat expectations, a boost for the company as it faces pressure from an activist investor ...

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the ...

Pfizer's diverse operations put it in an excellent position to grow in the long run. It doesn't have a top weight loss treatment on the market, but that could change. Its above-average dividend yield ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Company CEO Albert Bourla said Pfizer would consider “any good ideas” that create value, but argued it has already made ...

On Thursday, Pfizer Inc (PFE) stock saw a modest uptick, ending the day at $27.46 which represents a slight increase of $0.10 or 0.37% from the prior close of $27.36. The stock opened at $27.53 and ...

Pfizer reported an adjusted EPS of $1.06, exceeding estimates by over 72%. Revenue reached $17.7 billion, marking a 32% year ...